Previous close | 2.2900 |
Open | 2.1000 |
Bid | 1.3000 |
Ask | 1.6600 |
Strike | 920.00 |
Expiry date | 2024-06-21 |
Day's range | 1.6300 - 2.5100 |
Contract range | N/A |
Volume | |
Open interest | 237 |
Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.
The Nasdaq hit a new high Tuesday but Target tumbled early Wednesday. Will Nvidia earnings tonight meet lofty hopes?
(Bloomberg) -- Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics Inc. shares skyrocketing. But to reach the next level the biopharmaceutical developer likely needs a partner — or a buyer.Most Read from BloombergThese Flight Routes Suffer the World’s Worst TurbulenceOne Dead After Singapore Air Flight Hit By Severe TurbulenceCiti Trader Got 711 Warning Messages Before Sparking Flash Crash‘It Felt Like We Had Crashed’: Singapore Air Passenger Describes